Ayala Pharmaceuticals files Form 15 for voluntary deregistration and suspension of its reporting obligations

MONMOUTH JUNCTION, NJ, May 9, 2024 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it has filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and to suspend its reporting obligations pursuant to Section 15(d) of the Exchange Act. The Company’s obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of Form 15. Once the Form 15 becomes effective, which is expected to be within 90 days of filing, the Company will cease to be a publicly reporting company and its obligations to file further reports with the SEC will also be suspended.

About Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company with expertise in developing therapeutics to treat various types of cancer. For more information, visit www.ayalapharma.com.

Cautionary Statement Regarding Forward-Looking Statements

Forward-looking statements, such as the statement in this press release regarding the effectiveness of Form 15, are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Except as required by law, the Company undertakes no obligation to revise or update any forward-looking statements or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:
Ayala Pharmaceuticals:
+1-857-444-0553
[email protected]